Corporate Information
CEO Message
Mission
Corporate Information
Corporate Governance
Business
Stemrim History
About “Regeneration-Inducing Medicine
™
”
What is “Regeneration-Inducing Medicine
™
”?
Issues of Conventional Cell Therapy
The Superiority of “Regeneration-Inducing Medicine
™
”
Business
Areas of Disease and Pipeline
“Regeneration-Inducing Medicine
™
”
Autologous cell sampling devices for medical treatment
Stem cells gene therapy
Research Paper
Investor Relations
COO Message
Investor News
ESG
Financial Data
Investor Library
Investor Calendar
Analyst Coverage
Stock Prices
Investor Relations
Timely Disclosure Information
November 05, 2024
StemRIM Announces Patent Registration in Japan for the HMGB1 Peptide, Redasemtide
October 31, 2024
Presentation Material for Business Plan and Growth Potential
September 25, 2024
Notice Regarding Appointment of Director Candidates
September 25, 2024
StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators
September 11, 2024
Notice Regarding Differences between Non-consolidated Result s for Fiscal Year Ended July 31, 2024 and those for Previous Fiscal Year
Click here for past list
StemRIM
>
Investor Relations
>
Investor Library
>
Timely Disclosure Information